<DOC>
	<DOCNO>NCT00637247</DOCNO>
	<brief_summary>The purpose study determine imexon combination gemcitabine could improve overall survival compare gemcitabine alone subject pancreatic cancer spread organs liver lung . The study also look safety combination compare gemcitabine alone . Participants study randomly assign either treatment neither participant doctor know treatment receiving .</brief_summary>
	<brief_title>A Randomized Study Amplimexon ( Imexon ) With Gemcitabine Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm , chemotherapy naive , metastatic pancreatic adenocarcinoma ( Stage IV ) . This include patient locally advanced pancreatic cancer . 2 . At least one unidimensional measurable metastatic lesion contrast enhance CT scan ( MRI patient ineligible contrast enhance CT ) outside prior radiation port . 3 . Age least 18 year . 4 . ECOG performance status 0 1 . 5 . No prior chemotherapy radiation therapy . 6 . Projected life expectancy least 2 month . 7 . If female , neither pregnant lactating . 8 . If child bear potential must agree , able use adequate contraception . 9 . Concomitant disease : No respiratory insufficiency require oxygen therapy ; angina rest ; myocardial infarction previous 3 month ; life threaten ventricular arrhythmia . No uncompensated CHF NY Heart Association class 3 4 cardiac disease . 10 . No concurrent active malignancy . 11 . No infection require parenteral antibiotic therapy start protocol treatment . 12 . Laboratory value within follow criterion : Hgb great equal 9 gm/dL WBC great equal 3,500/mm^3 ANC great equal 1,500/mm^3 Platelet count great equal 100,000/mm^3 Creatinine great equal 2.0 Bilirubin less equal 2.0 Hepatic enzyme ( AST , ALT ) less equal 3 time upper limit normal ( ULN ) 13 . G6PD level great equal low limit normal ( LLN ) . 14 . Able render inform consent follow protocol requirement . 1 . Patients locally advance , nonmetastatic pancreas cancer ( Stage III ) . 2 . Age le 18 year . 3 . ECOG performance status 2 great . 4 . Prior anticancer drug therapy metastatic disease . 5 . Ascites . 6 . Prior abdominal thoracic surgery &lt; 4 week start therapy . 7 . Current prior brain metastasis . Brain MRI CT require preregistration patient CNS symptom indicate need evaluation . 8 . Life expectancy project less 2 month . 9 . Pregnancy lactation . 10 . Unable unwilling utilize medically acceptable contraception childbearing potential . 11 . Laboratory parameter outside specify range , ( see ) . 12 . Infection require parenteral antibiotic . 13 . NY Heart Association stage 3 4 heart disease . 14 . Unable render inform consent . 15 . Failure meet eligibility criterion outline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>chemotherapy naive</keyword>
</DOC>